Intercos (ICOS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Fiscal year marked by geopolitical tensions, market consolidation, and global beauty market softness, leading to a strategic focus on profitability recovery and higher value-added business over top-line growth.
Net sales reached €1,047.2 million, up 0.3% at constant FX but down 1.7% reported, impacted by lower pack sales and adverse FX movements.
Achieved structural improvements in profitability, with adjusted EBITDA up 8.8% to €156 million and margin expansion to 14.9% of net sales and 19.2% of value-added sales, the highest since IPO.
Maintained strong financial discipline, balancing investments, shareholder returns, and a solid balance sheet, with net debt stable at €100.5 million and leverage ratio at 0.64x.
Dividend proposal of €19 million and ongoing share buyback program up to 4% of share capital.
Financial highlights
Gross profit improved by €12.4 million to €219.4 million, with gross margin up 151bps to 21.0%.
Value-added sales were €812.8 million, up 1.5% at constant FX.
Adjusted net income increased to €57.4 million, up 1.3% year-over-year.
Operating cash flow after capex was €73.5 million, with cash conversion over 47% of EBITDA.
Net financial position excluding IFRS16 was €62.2 million.
Outlook and guidance
Forecasting 2026 sales growth of 5–6% reported, 6–7% at constant rates, outpacing expected market growth of 4%.
Growth expected to be weighted toward Q2 and the second half of 2026, with Q1 anticipated to be softer.
Margins expected to be at least flat or slightly improving in 2026.
Order intake in December 2025 was the highest ever, supporting a positive outlook.
Strategic expansion in China, South Korea, and emerging markets like India and Brazil.
Latest events from Intercos
- Record Q2 sales and EBITDA, with Hair & Body and EMEA leading growth; 2026 guidance confirmed.ICOS
Q2 2026 - Q1 2026 sales fell 6.3% at constant FX, but strong orders and innovation support a positive outlook.ICOS
Q1 2026 - Adjusted EBITDA up 12.3% in 9M25, with Make-up driving growth and margin improvement.ICOS
Q3 2025 - Strong Make-up growth drove sales and margin gains, despite net profit pressure from FX.ICOS
Q2 2025 - Record Q2 EBITDA and sales drive strong H1 and positive outlook for H2 2024.ICOS
Q2 2024 - Q3 sales and EBITDA up over 12%, driven by Asia and EMEA, with margin pressure ongoing.ICOS
Q3 2024 - Q1 2025 sales up 13.4% and EBITDA up 40.6%, driven by Make-up and multinational demand.ICOS
Q1 2025 - 2024 sales rose 7.8% to €1.06B, EBITDA up 4.3%, with strong Asia growth and 2025 guidance at 5–7%.ICOS
Q4 2024